A. Jungnik

发表

Safety, tolerability, pharmacokinetics and pharmacodynamics of single oral doses of BI 187004, an inhibitor of 11beta-hydroxysteroid dehydrogenase-1, in healthy male volunteers with overweight or obesity

T. Heise, C. Schepers, Susanna Bianzano, 2021, Clinical Diabetes and Endocrinology.

Bioequivalence of Linagliptin 5 mg once daily and 2.5 mg twice daily: pharmacokinetics and pharmacodynamics in an open-label crossover trial.

A. Ring, T. Meinicke, C. Friedrich, 2013, Drug research.

Comparative Pharmacokinetics of Azithromycin in Serum and White Blood Cells of Healthy Subjects Receiving a Single-Dose Extended-Release Regimen versus a 3-Day Immediate-Release Regimen

Amarnath Sharma, K. Phillips, Ping Liu, 2006, Antimicrobial Agents and Chemotherapy.

Pharmacodynamics and pharmacokinetics of the urotensin II receptor antagonist palosuran in macroalbuminuric, diabetic patients

S. Krähenbühl, A. Halabi, H. Chadha‐Boreham, 2006, Clinical pharmacology and therapeutics.

Pharmacokinetics and Pharmacodynamics of Single Rising Intravenous Doses (0.5mg–10mg) and Determination of Absolute Bioavailability of the Dipeptidyl Peptidase-4 Inhibitor Linagliptin (BI 1356) in Healthy Male Subjects

U. Jaehde, K. Dugi, S. Hüttner, 2010, Clinical pharmacokinetics.

Safety, tolerability, pharmacokinetics and pharmacodynamics of single oral doses of BI 187004, an inhibitor of 11beta-hydroxysteroid dehydrogenase-1, in healthy male volunteers with overweight or obesity

T. Heise, C. Schepers, Susanna Bianzano, 2020, Clinical Diabetes and Endocrinology.

Safety, pharmacokinetics and pharmacodynamics of BI 135585, a selective 11β‐hydroxysteroid dehydrogenase‐1 (HSD1) inhibitor in humans: liver and adipose tissue 11β‐HSD1 inhibition after acute and multiple administrations over 2 weeks

T. Heise, H. Woerle, H. Woerle, 2016, Diabetes, obesity & metabolism.

Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon‐like peptide‐1 receptor agonist BI 456906

C. Kapitza, A. Hennige, D. Lamers, 2022, Diabetes, obesity & metabolism.

Effect of food on the pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, and assessment of dose proportionality in healthy volunteers.

K. Hohl, H. Woerle, A. Salsali, 2013, International journal of clinical pharmacology and therapeutics.

Pharmacokinetic Drug Interactions of Afatinib with Rifampicin and Ritonavir

T. Giessmann, P. Stopfer, S. Wind, 2014, Clinical Drug Investigation.

Effects of Ketoconazole and Rifampicin on the Pharmacokinetics of Nintedanib in Healthy Subjects

Claudia Dallinger, A. Jungnik, K. Marzin, 2018, European Journal of Drug Metabolism and Pharmacokinetics.

Effects of Metformin and Furosemide on Rosuvastatin Pharmacokinetics in Healthy Volunteers: Implications for Their Use as Probe Drugs in a Transporter Cocktail

Mitchell E Taub, Fabian Müller, Thomas Ebner, 2017, European Journal of Drug Metabolism and Pharmacokinetics.

Effects of Metformin and Furosemide on Rosuvastatin Pharmacokinetics in Healthy Volunteers: Implications for Their Use as Probe Drugs in a Transporter Cocktail

F. Müller, K. Hohl, M. Taub, 2017, European Journal of Drug Metabolism and Pharmacokinetics.